Gilead Sciences' CEO Daniel O'Day said the company's experimental COVID-19 treatment remdesivir will be available to patients "in the early part of this next week," reported CNBC.
He noted that Gilead is "beginning to work with the government which will determine which cities are most vulnerable and where the patients are that need this medicine."
"We've donated the entire supply that we have within our supply chain and we did that because we acknowledge and recognize the human suffering, the human need here, and want to make sure nothing gets in the way of this getting to patients," O'Day added.
Gilead expects to produce more than 140,000 rounds of its 10-day treatment regimen by the end of May and anticipates it can make 1 million rounds by the end of this year.
To read more NewsPoints articles, click here.